vs
Ginkgo Bioworks Holdings, Inc.（DNA）与GREENE COUNTY BANCORP INC（GCBC）财务数据对比。点击上方公司名可切换其他公司
Ginkgo Bioworks Holdings, Inc.的季度营收约是GREENE COUNTY BANCORP INC的1.5倍（$33.4M vs $22.2M），GREENE COUNTY BANCORP INC同比增速更快（23.8% vs -23.8%），GREENE COUNTY BANCORP INC自由现金流更多（$6.2M vs $-47.7M），过去两年GREENE COUNTY BANCORP INC的营收复合增速更高（18.9% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
格林县银行股份公司是一家总部位于纽约州卡茨基尔的美国联邦注册储蓄银行，营业网点分布于纽约上州的格林县、哥伦比亚县、奥尔巴尼县、阿尔斯特县和伦斯勒县，主要服务纽约上州对应区域的客户与当地社区。
DNA vs GCBC — 直观对比
营收规模更大
DNA
是对方的1.5倍
$22.2M
营收增速更快
GCBC
高出47.6%
-23.8%
自由现金流更多
GCBC
多$53.9M
$-47.7M
两年增速更快
GCBC
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $22.2M |
| 净利润 | — | $10.3M |
| 毛利率 | — | — |
| 营业利润率 | -211.9% | 52.0% |
| 净利率 | — | 46.3% |
| 营收同比 | -23.8% | 23.8% |
| 净利润同比 | — | 37.4% |
| 每股收益（稀释后） | $-1.41 | $0.60 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNAGCBC
| Q4 25 | $33.4M | $22.2M | ||
| Q3 25 | $38.8M | $21.5M | ||
| Q2 25 | $49.6M | $20.5M | ||
| Q1 25 | $48.3M | $20.1M | ||
| Q4 24 | $43.8M | $17.9M | ||
| Q3 24 | $89.0M | $16.9M | ||
| Q2 24 | $56.2M | $16.6M | ||
| Q1 24 | $37.9M | $15.7M |
净利润DNAGCBC
| Q4 25 | — | $10.3M | ||
| Q3 25 | $-80.8M | $8.9M | ||
| Q2 25 | $-60.3M | $9.3M | ||
| Q1 25 | $-91.0M | $8.1M | ||
| Q4 24 | — | $7.5M | ||
| Q3 24 | $-56.4M | $6.3M | ||
| Q2 24 | $-217.2M | $6.7M | ||
| Q1 24 | $-165.9M | $5.9M |
营业利润率DNAGCBC
| Q4 25 | -211.9% | 52.0% | ||
| Q3 25 | -231.8% | 47.4% | ||
| Q2 25 | -132.1% | 53.5% | ||
| Q1 25 | -184.1% | 44.6% | ||
| Q4 24 | -236.3% | 45.0% | ||
| Q3 24 | -62.0% | 39.6% | ||
| Q2 24 | -396.7% | 41.2% | ||
| Q1 24 | -469.1% | 39.4% |
净利率DNAGCBC
| Q4 25 | — | 46.3% | ||
| Q3 25 | -207.9% | 41.2% | ||
| Q2 25 | -121.6% | 45.6% | ||
| Q1 25 | -188.2% | 40.1% | ||
| Q4 24 | — | 41.7% | ||
| Q3 24 | -63.3% | 37.1% | ||
| Q2 24 | -386.4% | 40.6% | ||
| Q1 24 | -437.3% | 37.3% |
每股收益（稀释后）DNAGCBC
| Q4 25 | $-1.41 | $0.60 | ||
| Q3 25 | $-1.45 | $0.52 | ||
| Q2 25 | $-1.10 | $0.55 | ||
| Q1 25 | $-1.68 | $0.47 | ||
| Q4 24 | $-1.91 | $0.44 | ||
| Q3 24 | $-1.08 | $0.37 | ||
| Q2 24 | $-4.23 | $0.39 | ||
| Q1 24 | $-3.32 | $0.34 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $508.6M | $258.3M |
| 总资产 | $1.1B | $3.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DNAGCBC
| Q4 25 | $422.6M | — | ||
| Q3 25 | $495.5M | — | ||
| Q2 25 | $559.4M | — | ||
| Q1 25 | $325.3M | $155.5M | ||
| Q4 24 | $561.6M | $166.4M | ||
| Q3 24 | $616.2M | — | ||
| Q2 24 | $730.4M | $190.4M | ||
| Q1 24 | $840.4M | — |
股东权益DNAGCBC
| Q4 25 | $508.6M | $258.3M | ||
| Q3 25 | $559.8M | $248.2M | ||
| Q2 25 | $613.0M | $238.8M | ||
| Q1 25 | $647.4M | $229.0M | ||
| Q4 24 | $716.1M | $218.4M | ||
| Q3 24 | $797.9M | $216.3M | ||
| Q2 24 | $833.1M | $206.0M | ||
| Q1 24 | $987.3M | $199.2M |
总资产DNAGCBC
| Q4 25 | $1.1B | $3.1B | ||
| Q3 25 | $1.2B | $3.1B | ||
| Q2 25 | $1.2B | $3.0B | ||
| Q1 25 | $1.3B | $3.0B | ||
| Q4 24 | $1.4B | $3.0B | ||
| Q3 24 | $1.5B | $2.9B | ||
| Q2 24 | $1.6B | $2.8B | ||
| Q1 24 | $1.6B | $2.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $6.4M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | $6.2M |
| 自由现金流率自由现金流/营收 | -142.8% | 28.0% |
| 资本支出强度资本支出/营收 | 0.0% | 0.9% |
| 现金转化率经营现金流/净利润 | — | 0.62× |
| 过去12个月自由现金流最近4个季度 | — | $47.3M |
8季度趋势，按日历期对齐
经营现金流DNAGCBC
| Q4 25 | $-47.7M | $6.4M | ||
| Q3 25 | $-31.6M | $7.0M | ||
| Q2 25 | $-40.3M | $28.0M | ||
| Q1 25 | $-51.5M | $7.3M | ||
| Q4 24 | $-42.4M | $5.3M | ||
| Q3 24 | $-103.5M | $2.1M | ||
| Q2 24 | $-84.4M | $24.9M | ||
| Q1 24 | $-89.3M | $5.6M |
自由现金流DNAGCBC
| Q4 25 | $-47.7M | $6.2M | ||
| Q3 25 | — | $6.5M | ||
| Q2 25 | $-40.3M | $27.3M | ||
| Q1 25 | $-59.1M | $7.3M | ||
| Q4 24 | $-56.1M | $5.1M | ||
| Q3 24 | $-118.6M | $2.0M | ||
| Q2 24 | $-111.4M | $23.4M | ||
| Q1 24 | $-96.0M | $4.9M |
自由现金流率DNAGCBC
| Q4 25 | -142.8% | 28.0% | ||
| Q3 25 | — | 30.4% | ||
| Q2 25 | -81.2% | 133.3% | ||
| Q1 25 | -122.4% | 36.1% | ||
| Q4 24 | -128.0% | 28.6% | ||
| Q3 24 | -133.2% | 11.8% | ||
| Q2 24 | -198.2% | 141.2% | ||
| Q1 24 | -252.9% | 31.3% |
资本支出强度DNAGCBC
| Q4 25 | 0.0% | 0.9% | ||
| Q3 25 | 0.0% | 1.9% | ||
| Q2 25 | 0.1% | 3.4% | ||
| Q1 25 | 15.8% | 0.3% | ||
| Q4 24 | 31.3% | 1.0% | ||
| Q3 24 | 16.9% | 0.9% | ||
| Q2 24 | 48.1% | 9.1% | ||
| Q1 24 | 17.7% | 4.2% |
现金转化率DNAGCBC
| Q4 25 | — | 0.62× | ||
| Q3 25 | — | 0.78× | ||
| Q2 25 | — | 3.00× | ||
| Q1 25 | — | 0.91× | ||
| Q4 24 | — | 0.71× | ||
| Q3 24 | — | 0.34× | ||
| Q2 24 | — | 3.70× | ||
| Q1 24 | — | 0.95× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
GCBC
暂无分部数据
